Mitchell Sullivan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Industrial Pkwy, Lyndonville, VT 05851 Phone: 802-748-9501 Fax: 802-748-3420 |
News Archive
Celgene International Sàrl today announced that its next IMiD compound, pomalidomide, was evaluated in three separate investigational trials of patients with multiple myeloma who were relapsed or refractory after prior treatments including lenalidomide, thalidomide and bortezomib. The clinical data were presented at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.
Baby diapers, contact lenses and gelatin dessert. While seemingly unrelated, these items have one thing in common - they're made of highly absorbent substances called hydrogels that have versatile applications.
Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced today that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma's drug candidate tosedostat in North, Central and South America.
Silence Therapeutics plc announces the issuance of patent 4,705,370, titled "Further Novel Forms of Interfering RNA Molecules," by the Japanese Patent Office.
› Verified 3 days ago